07:00 , Apr 25, 2011 |  BC Week In Review  |  Company News

Cardiogenesis, CryoLife deal

CryoLife said Cardiogenesis did not receive alternative acquisition offers during the 20-day period it was allowed to engage third parties. Earlier this month, CryoLife began a previously announced tender offer to acquire Cardiogenesis for $0.46...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Cardiogenesis, CryoLife deal

CryoLife began its previously announced tender offer to acquire Cardiogenesis for $0.46 per share, or about $22 million. The offer will expire at the end of May 2 (see BioCentury, April 4). Cardiogenesis Corp. (OTCBB:CGCP),...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Cardiogenesis, CryoLife deal

CryoLife will acquire Cardiogenesis for $0.46 per share, or about $22 million in cash. The price is a 43% premium to Cardiogenesis' close of $0.32 on March 28, before the deal was announced. The deal,...
08:00 , Dec 7, 1998 |  BC Week In Review  |  Clinical News

CardioGenesis Corp. regulatory update

U.S. Patent No. 5,840,059, covering administration of angiogenic growth factors as part of therapy for severe angina resulting from coronary artery disease, issued to CGCP, Indiana University (Bloomington, Ind.) and Columbia University (New York, N.Y.)....
07:00 , Apr 21, 1997 |  BC Week In Review  |  Company News

CardioGenesis Corp., Chiron deal

The companies will develop methods to enhance transmyocardial revascularization (TMR) to treat myocardial ischemia. CHIR will provide certain cardiovascular compounds, and CGCP will provide its epicardial and endocardial TMR technologies to a preclinical research program....